Literature DB >> 26973240

Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.

P German1, S Bai1, X-D Liu1, M Sun1, L Zhou1, S Kalra1, X Zhang1, R Minelli2, K L Scott2, G B Mills3, E Jonasch1, Z Ding3.   

Abstract

Loss of von Hippel Lindau (VHL) protein function is a key driver of VHL diseases, including sporadic and inherited clear cell renal cell carcinoma. Modulation of the proteostasis of VHL, especially missense point-mutated VHL, is a promising approach to augmenting VHL levels and function. VHL proteostasis is regulated by multiple mechanisms including folding, chaperone binding, complex formation and phosphorylation. Nevertheless, many details underlying the regulations of VHL proteostasis are unknown. VHL is expressed as two variants, VHL30 and VHL19. Furthermore, the long-form variant of VHL was often detected as multiple bands by western blotting. However, how these multiple species of VHL are generated and whether the process regulates VHL proteostasis and function are unknown. We hypothesized that the two major species are generated by VHL protein cleavage, and the cleavage regulates VHL proteostasis and subsequent function. We characterized VHL species using genetical and pharmacological approaches and showed that VHL was first cleaved at the N-terminus by chymotrypsin C before being directed for proteasomal degradation. Casein kinase 2-mediated phosphorylation at VHL N-terminus was required for the cleavage. Furthermore, inhibition of cleavage stabilized VHL protein and thereby promoted HIF downregulation. Our study reveals a novel mechanism regulating VHL proteostasis and function, which is significant for identifying new drug targets and developing new therapeutic approaches targeting VHL deficiency in VHL diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26973240      PMCID: PMC5086402          DOI: 10.1038/onc.2016.40

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding.

Authors:  Douglas E Feldman; Christoph Spiess; Daniel E Howard; Judith Frydman
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

Review 2.  Protein kinase CK2 and angiogenesis.

Authors:  Mathias Montenarh
Journal:  Adv Clin Exp Med       Date:  2014 Mar-Apr       Impact factor: 1.727

3.  Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products.

Authors:  A R Schoenfeld; E J Davidowitz; R D Burk
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

5.  Protein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells.

Authors:  Barbara Guerra; Tine D L Rasmussen; Alexander Schnitzler; Hans H Jensen; Brigitte S Boldyreff; Yoshihiko Miyata; Niels Marcussen; Karsten Niefind; Olaf-Georg Issinger
Journal:  Cancer Lett       Date:  2014-10-28       Impact factor: 8.679

6.  Asymmetric expression of protein kinase CK2 subunits in human kidney tumors.

Authors:  G Stalter; S Siemer; E Becht; M Ziegler; K Remberger; O G Issinger
Journal:  Biochem Biophys Res Commun       Date:  1994-07-15       Impact factor: 3.575

7.  Proteostasis modulators prolong missense VHL protein activity and halt tumor progression.

Authors:  Chunzhang Yang; Kristin Huntoon; Alexander Ksendzovsky; Zhengping Zhuang; Russell R Lonser
Journal:  Cell Rep       Date:  2013-01-10       Impact factor: 9.423

8.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

Authors:  Rosamonde E Banks; Prasanna Tirukonda; Claire Taylor; Nick Hornigold; Dewi Astuti; Dena Cohen; Eamonn R Maher; Anthea J Stanley; Patricia Harnden; Adrian Joyce; Margaret Knowles; Peter J Selby
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

Review 9.  von Hippel-Lindau disease.

Authors:  Russell R Lonser; Gladys M Glenn; McClellan Walther; Emily Y Chew; Steven K Libutti; W Marston Linehan; Edward H Oldfield
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321

10.  Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.

Authors:  Marco Pizzi; Francesco Piazza; Claudio Agostinelli; Fabio Fuligni; Pietro Benvenuti; Elisa Mandato; Alessandro Casellato; Massimo Rugge; Gianpietro Semenzato; Stefano A Pileri
Journal:  Oncotarget       Date:  2015-03-30
View more
  6 in total

1.  The long form of pVHL is artifactually modified by serine protease inhibitor AEBSF.

Authors:  Daniel Tarade; Shelley He; Jonathan St-Germain; Avi Petroff; Anya Murphy; Brian Raught; Michael Ohh
Journal:  Protein Sci       Date:  2020-06-25       Impact factor: 6.725

Review 2.  CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.

Authors:  Melissa M J Chua; Charina E Ortega; Ayesha Sheikh; Migi Lee; Hussein Abdul-Rassoul; Kevan L Hartshorn; Isabel Dominguez
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-28

3.  Cell-based screen identifies a new potent and highly selective CK2 inhibitor for modulation of circadian rhythms and cancer cell growth.

Authors:  Tsuyoshi Oshima; Yoshimi Niwa; Keiko Kuwata; Ashutosh Srivastava; Tomoko Hyoda; Yoshiki Tsuchiya; Megumi Kumagai; Masato Tsuyuguchi; Teruya Tamaru; Akiko Sugiyama; Natsuko Ono; Norjin Zolboot; Yoshiki Aikawa; Shunsuke Oishi; Atsushi Nonami; Fumio Arai; Shinya Hagihara; Junichiro Yamaguchi; Florence Tama; Yuya Kunisaki; Kazuhiro Yagita; Masaaki Ikeda; Takayoshi Kinoshita; Steve A Kay; Kenichiro Itami; Tsuyoshi Hirota
Journal:  Sci Adv       Date:  2019-01-23       Impact factor: 14.136

4.  The pVHL neglected functions, a tale of hypoxia-dependent and -independent regulations in cancer.

Authors:  Giovanni Minervini; Maria Pennuto; Silvio C E Tosatto
Journal:  Open Biol       Date:  2020-07-01       Impact factor: 6.411

Review 5.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.

Authors:  Eric Jonasch; Cheryl Lyn Walker; W Kimryn Rathmell
Journal:  Nat Rev Nephrol       Date:  2020-11-03       Impact factor: 28.314

6.  Ancient Evolutionary Origin of Intrinsically Disordered Cancer Risk Regions.

Authors:  Mátyás Pajkos; András Zeke; Zsuzsanna Dosztányi
Journal:  Biomolecules       Date:  2020-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.